Last reviewed · How we verify
Ondansetron Intraperitoneal Lavage
Ondansetron blocks serotonin 5-HT3 receptors in the peritoneal cavity to prevent nausea and vomiting during intraperitoneal lavage procedures.
Ondansetron blocks serotonin 5-HT3 receptors in the chemoreceptor trigger zone and gastrointestinal tract to prevent nausea and vomiting. Used for Prevention of postoperative nausea and vomiting (PONV) following abdominal surgery via intraperitoneal administration.
At a glance
| Generic name | Ondansetron Intraperitoneal Lavage |
|---|---|
| Also known as | Ondansetron, Zofran, 0.9% Sodium Chloride |
| Sponsor | Instituto Mexicano del Seguro Social |
| Drug class | 5-HT3 receptor antagonist |
| Target | 5-HT3 receptor |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology / Oncology |
| Phase | FDA-approved |
Mechanism of action
Ondansetron is a selective 5-HT3 receptor antagonist that works locally when instilled into the peritoneal cavity during lavage procedures. By blocking serotonin signaling at chemoreceptor trigger zone and vagal afferent pathways, it reduces the emetogenic stimulus associated with peritoneal manipulation and fluid instillation. This local application may provide targeted antiemetic effects with potentially reduced systemic exposure compared to parenteral administration.
Approved indications
- Prevention of nausea and vomiting associated with intraperitoneal lavage procedures
Common side effects
- Headache
- Constipation
- Dizziness
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: